Biotechnology Acquisitions

Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...